Novo Nordisk A/S (NVO) delivered a first-quarter report that looked impressive at first glance. Net sales reached DKK 96,823 million, up 24% in Danish kroner and 32% at constant exchange rates, while reported operating profit rose to DKK 59,618 million, up 54% in kroner and 65% at CER. Management also raised its 2026 outlook, citing stronger expectations for GLP-1 product sales.
But the headline growth rates do not tell the full story. Once the company’s non-recurring 340B provision reversal is stripped out, the quarter looks materially softer. Adjusted net sales were DKK 70,063 million, down 10% in kroner and 4% at CER, while adjusted operating profit was DKK 32,858 million, down 15% in kroner and 6% at CER. For investors, that makes this a much more nuanced quarter than the initial top-line beat suggests.
What the Headline Q1 Numbers Say
The headline figures support the idea that Novo Nordisk remains one of the most important growth stories in large-cap healthcare. Reported sales and reported operating profit both increased sharply, and management was confident enough to lift its outlook for the year.
That confidence is not hard to understand. Novo continues to benefit from enormous demand for GLP-1 therapies, and the company’s product pipeline also added supporting milestones during the quarter, including FDA approval for Wegovy HD and approval of Awiqli, its once-weekly basal insulin for type 2 diabetes.
If investors look only at the reported figures and the higher guidance, the quarter reads like another clean confirmation that Novo still controls one of the strongest franchises in global pharmaceuticals.
Why Wegovy Pill Is Driving the Story
The real operating highlight was the early launch trajectory of Wegovy pill in the U.S. Novo said the therapy generated Q1 2026 sales of DKK 2,256 million after its January launch. Total prescriptions since launch have now surpassed 2 million, and weekly prescriptions exceeded 200,000 by the week ending April 17.
Those are striking numbers because they suggest Novo may be opening a new growth lane rather than merely extending its injectable obesity franchise. Management described the product as the strongest-ever GLP-1 volume launch in the U.S., and the quarter’s raised guidance was explicitly tied to stronger expectations for GLP-1 sales.
Obesity care remains the center of the story. Adjusted obesity-care sales increased 22% at CER, reinforcing the view that Novo still has meaningful demand momentum even as competition in the category continues to intensify.
What the Adjusted Figures Reveal About Pricing Pressure
The complication is that the underlying business was not as strong as the headline growth rates imply. The reported numbers were boosted by a non-recurring provision reversal related to the 340B Drug Pricing Program in the U.S. Excluding that benefit, both adjusted sales and adjusted operating profit declined.
That softer underlying picture appears to be driven largely by pricing pressure in the U.S. Novo said adjusted U.S. sales fell 11% at CER because of lower realized prices, even though volume growth across the Wegovy portfolio remained strong. International Operations were healthier, with sales up 6% at CER, but the U.S. pricing dynamic is the key issue investors cannot ignore.
This is the tension in the stock now. Novo can still report powerful headline growth and launch momentum, yet the economics beneath those numbers are becoming more contested. That does not break the bull case, but it does make the next few quarters more important in determining how durable GLP-1 profitability really is.
What the Raised Outlook Means for the GLP-1 Growth Narrative
The raised outlook is still meaningful because it shows management believes the demand backdrop is strong enough to offset at least part of the pricing pressure. Novo now expects adjusted sales growth for 2026, excluding the 340B reversal, of negative 4% to negative 12% at CER and adjusted operating-profit growth in the same range.
That guidance is not as strong as the headline quarter might initially suggest, but it does indicate management sees enough support from the Wegovy franchise to improve expectations. In effect, Novo is telling investors that volume growth and product momentum remain powerful, even if pricing and mix are making the path less straightforward.
For the market, the takeaway is clear: the quarter was good enough to support a higher outlook, but not clean enough to remove doubts about underlying pricing power in the U.S. obesity business.
Key Signals for Investors
Reported Q1 growth was strong, but the adjusted figures show the quarter depended heavily on a one-time 340B-related benefit.
Wegovy pill sales of DKK 2,256 million and more than 2 million prescriptions since launch point to a potentially major new growth driver.
Adjusted U.S. sales fell 11% at CER, making realized pricing the most important operating risk to watch.
International sales growth of 6% at CER provides some diversification, but it does not fully offset pressure in the U.S. base.
The higher 2026 outlook supports the long-term GLP-1 thesis, yet investors will likely demand cleaner underlying growth in coming quarters.
